238 related articles for article (PubMed ID: 2340521)
1. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation.
Kyprianou N; English HF; Isaacs JT
Cancer Res; 1990 Jun; 50(12):3748-53. PubMed ID: 2340521
[TBL] [Abstract][Full Text] [Related]
2. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation.
Kyprianou N; English HF; Davidson NE; Isaacs JT
Cancer Res; 1991 Jan; 51(1):162-6. PubMed ID: 1899037
[TBL] [Abstract][Full Text] [Related]
3. Programmed death of nonproliferating androgen-independent prostatic cancer cells.
Martikainen P; Kyprianou N; Tucker RW; Isaacs JT
Cancer Res; 1991 Sep; 51(17):4693-700. PubMed ID: 1873814
[TBL] [Abstract][Full Text] [Related]
4. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
Miyake H; Chi KN; Gleave ME
Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
6. Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells.
Gao J; Isaacs JT
Cancer Res; 1998 Aug; 58(15):3299-306. PubMed ID: 9699659
[TBL] [Abstract][Full Text] [Related]
7. Androgen regulation of programmed death of normal and malignant prostatic cells.
Isaacs JT; Lundmo PI; Berges R; Martikainen P; Kyprianou N; English HF
J Androl; 1992; 13(6):457-64. PubMed ID: 1293127
[TBL] [Abstract][Full Text] [Related]
8. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
Joseph IB; Nelson JB; Denmeade SR; Isaacs JT
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654
[TBL] [Abstract][Full Text] [Related]
9. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer.
Denmeade SR; Lin XS; Isaacs JT
Prostate; 1996 Apr; 28(4):251-65. PubMed ID: 8602401
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
Miyake H; Nelson C; Rennie PS; Gleave ME
Cancer Res; 2000 May; 60(9):2547-54. PubMed ID: 10811138
[TBL] [Abstract][Full Text] [Related]
11. Phorbol ester-induced apoptosis is accompanied by NGFI-A and c-fos activation in androgen-sensitive prostate cancer cells.
Day ML; Zhao X; Wu S; Swanson PE; Humphrey PA
Cell Growth Differ; 1994 Jul; 5(7):735-41. PubMed ID: 7947388
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
14. Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468.
Armstrong DK; Isaacs JT; Ottaviano YL; Davidson NE
Cancer Res; 1992 Jun; 52(12):3418-24. PubMed ID: 1534511
[TBL] [Abstract][Full Text] [Related]
15. Programmed cell death as a new target for prostatic cancer therapy.
Kyprianou N; Martikainen P; Davis L; English HF; Isaacs JT
Cancer Surv; 1991; 11():265-77. PubMed ID: 1841755
[TBL] [Abstract][Full Text] [Related]
16. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide.
Vukanovic J; Isaacs JT
Cancer Res; 1995 Aug; 55(16):3517-20. PubMed ID: 7543015
[TBL] [Abstract][Full Text] [Related]
17. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.
Amler LC; Agus DB; LeDuc C; Sapinoso ML; Fox WD; Kern S; Lee D; Wang V; Leysens M; Higgins B; Martin J; Gerald W; Dracopoli N; Cordon-Cardo C; Scher HI; Hampton GM
Cancer Res; 2000 Nov; 60(21):6134-41. PubMed ID: 11085537
[TBL] [Abstract][Full Text] [Related]
18. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
20. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
